312
Participants
Start Date
August 31, 2007
Primary Completion Date
November 30, 2010
Study Completion Date
October 31, 2012
carfilzomib
Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
carfilzomib
Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
St. Vincent Catholic Medical Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pennsylvania, Philadelphia
Wake Forest University, Winston-Salem
Emory University Winship Cancer Institute, Atlanta
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Florida Cancer Specialists, Fort Myers
Southern Cancer Center, Mobile
Sarah Cannon Research Institute, Nashville
University of Kentucky, Lexington
Cleveland Clinic, Cleveland
Gabrail Cancer Center, Canton
Oncology & Hematology Care, Cincinnati
University of Michigan, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
Mayo Clinic - Rochester, Rochester
Northwestern Universtiy, Chicago
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
MD Anderson Cancer Center, Houston
Northwest Cancer Center, Houston
University of Utah, Salt Lake City
Mayo Clinic Scottsdale, Scottsdale
Tower Cancer Research Foundation, Beverly Hills
City of Hope National Medical Center, Duarte
Scripps Clinic, La Jolla
University of California, San Francisco, San Francisco
Hackensack University Medical Center, Hackensack
University of Calgary, Calgary
University of Alberta, Cross Cancer Institute, Edmonton
Leukemia/BMT Program of BC, Vancouver
Princess Margaret Hospital, Toronto
Royal Victoria Hospital, Montreal
Jewish General Hospital, Montreal
Lead Sponsor
Amgen
INDUSTRY